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Renal Fanconi syndrome occurs in about 1–5% of all children
treated with Ifosfamide (Ifo) and impairment of renal
phosphate reabsorption in about 20–30% of them.
Pathophysiological mechanisms of Ifo-induced nephropathy
are ill defined. The aim has been to investigate whether Ifo
metabolites affect the type IIa sodium-dependent phosphate
transporter (NaPi-IIa) in viable opossum kidney cells. Ifo
did not influence viability of cells or NaPi-IIa-mediated
transport up to 1 mM/24 h. Incubation of confluent cells with
chloroacetaldehyde (CAA) and 4-hydroperoxyIfosfamide
(4-OH-Ifo) led to cell death by necrosis in a
concentration-dependent manner. At low concentrations
(50–100 lM/24 h), cell viability was normal but apical
phosphate transport, NaPi-IIa protein, and -mRNA expression
were significantly reduced. Coincubation with
sodium-2-mercaptoethanesulfonate (MESNA) prevented the
inhibitory action of CAA but not of 4-OH-Ifo; DiMESNA had
no effect. Incubation with Ifosfamide-mustard (Ifo-mustard)
did alter cell viability at concentrations above 500 lM/24 h. At
lower concentrations (50–100lM/24 h), it led to significant
reduction in phosphate transport, NaPi-IIa protein, and
mRNA expression. MESNA did not block these effects. The
effect of Ifo-mustard was due to internalization of NaPi-IIa.
Cyclophosphamide-mustard (CyP-mustard) did not have any
influence on cell survival up to 1000 lM, but the inhibitory
effect on phosphate transport and on NaPi-IIa protein was
the same as found after Ifo-mustard. In conclusion, CAA,
4-OH-Ifo, and Ifo- and CyP-mustard are able to inhibit
sodium-dependent phosphate cotransport in viable opossum
kidney cells. The Ifo-mustard effect took place via
internalization and reduction of de novo synthesis of NaPi-IIa.
Therefore, it is possible that Ifo-mustard plays an important
role in pathogenesis of Ifo-induced nephropathy.
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Ifosfamide (Ifo) is an alkylating agent with considerable
activity against a wide range of childhood malignancies. The
most important side effect, the renal Fanconi syndrome (FS),
occurs in about 1–5% of all children treated with Ifo, whereas
impairment of renal phosphate reabsorption occurs in about
20–30% of them.1,2
Pathophysiological mechanisms of Ifo-induced nephro-
pathy are ill defined.3 Concepts suggest blockage of energy
production (adenosine triphosphate (ATP)-depletion) by
binding of toxic metabolites to mitochondrial DNA or
blockage of cell regeneration by binding to nuclear DNA.
Furthermore, depletion of glutathione in the proximal tubule
caused by sodium-2-mercaptoethanesulfonate (MESNA),
leading to an enhanced susceptibility to oxidative stress by
free radicals, was proposed. In clinical conditions, Ifo and
cyclophosphamide (CyP) are always given in combination
with MESNA to prevent hemorrhagic cystitis. MESNA is a
thiol compound that functions as a regional detoxificant of
urotoxic Ifo metabolites such as acrolein, 4-hydroperoxy-
Ifosfamide (4-OH-Ifo), and chloroacetaldehyde (CAA). After
entering the circulation, MESNA is oxidized to DiMESNA,
which is then excreted by the kidneys.4 Between 30 and 50%
of glomerularly filtered DiMESNA is reduced back to
MESNA in renal tubular cells by glutathione reductase. The
resulting free sulfhydryl groups of MESNA can combine
directly with the double bond of acrolein, or with other toxic
oxazaphosphorine metabolites in the bladder to form stable
and non-toxic compounds.5 As MESNA causes glutathione
depletion in plasma and renal tubular cells, this may lead to
the loss of intracellular redox potential and could also
contribute to cell injury by Ifo.6
Hitherto, important questions have remained with all
these concepts such as what are the causative metabolites, and
what causes the difference to isomeric CyP, as neither FS nor
proximal tubular damage has been reported following a
treatment with the latter drug. It is unclear why does the
tubulopathy often become apparent months after treatment
has ended and what is the role of MESNA.
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Recently, it has been shown that side-chain oxidation of
Ifo takes place in human pediatric kidneys mediated by
cytochromes P4503A and P4502B6.7 Both Ifo and CyP are
metabolized by hydroxylation and side-chain oxidation.8,9 In
CyP, 1–2% is metabolized by side-chain oxidation to CAA,
whereas in Ifo this pathway accounts for 25–60%. Conse-
quently, the concentration of CAA in serum has been found
to be 100 times higher in patients treated with Ifo compared
with CyP.10 Therefore, CAA was assumed to be at least
responsible, in part, for the nephrotoxicity of Ifo. This
finding was published by Zamlauski-Tucker et al.11 using
isolated perfused rat kidneys and subsequently by Spring-
ate,12 who found glomerular and tubular changes associated
with glutathione depletion and malondialdehyde accumula-
tion after intrarenal CAA infusion.
Investigations regarding the effect of oxazaphosphorines at
a cellular level are rare. CAA produced dose-dependent
declines in neutral red dye uptake, ATP levels, glutathione
content, and cell growth13 or thymidine incorporation.14
Dubourg et al.15 described similar toxicity of CAA on isolated
adult and pediatric kidney tubules, again with cellular
depletion of thiol compounds, that is, glutathione, coenzyme
A, and acetyl-coenzyme A. Mohrmann et al.16 investigated the
effects of CAA, 4-OH-Ifo, and acrolein on LLCPK1 cells; they
described both stimulating and inhibiting effects on the
cellular phosphate transport, depending on the concentration,
as well as a reduction in Na-K-ATPase and succinate-
cytochrome-c-oxidase activities. These experiments need
interpreting with caution because LLCPK1 cells do not express
parathyroid hormone (PTH)-inhibitable type IIa sodium-
dependent phosphate transporter (NaPi-IIa) cotransporter.
So in our opinion, there is evidence that, in patients treated
with Ifo, CAA as a product of side-chain oxidation may cause
more toxic effects leading to cell death as compared with CyP.
However, there is no proof that this may be the cause for long-
term dysfunction of the proximal tubule.
Recently, it was shown that certain types of renal FS may
be caused by alterations to the apical transporter system. In
Dent’s disease (OMIM 300009), mutation of the CLCN5 gene
impairs function of an apical chloride channel17–19 followed
by reduced acidification of endosomes with consecutive
reduced apical expression of NaPi-IIa and NHE3.20–24 In
Lowe syndrome (OMIM 309000), impaired phosphatidyl-
inositol-4,5-biphosphatase activity causes disruption of
megalin recycling.25,26 Therefore, impairment of endocytosis
and recycling of apical transporters may be a pathophysio-
logical principle in some renal tubulopathies.
In the study presented here, we aimed to investigate
whether metabolites of Ifo affect the activity and/or
expression of NaPi-IIa in viable opossum kidney cells (OK
cells) in culture. NaPi-IIa was chosen as a model firstly
because it appears to be of crucial importance for overall
renal Pi reabsorption as well as for adjustments in and
alterations to normal and pathophysiological conditions as
reviewed in several recent articles,27–29 and secondly because
impairment of renal Pi reabsorption is beside renal tubular
acidosis the most clinically important side effect of Ifo
treatment in children.
RESULTS
Incubation with Ifo and CyP did not influence cell survival
and sodium-dependent phosphate cotransport (Pi transport)
up to 1000 mM/24 h. Also, incubation with 0.3, 1, and 3 mM
MESNA or DiMESNA for 6 or 24 h did not have any effect on
these parameters (data not shown).
CAA
CAA has a short half-life in vivo (2–8 min in humans30 and
50 min in rats,31 respectively). Therefore, we first analyzed the
stability of CAA in our incubation medium in collaboration
with Dr Th Wagner (Department of Internal Medicine,
University of Luebeck). CAA (20 mmol/l) were degraded by
zero-order kinetic with a half-life of 11.9 h.
By testing cell survival and Pi transport at different
incubation times (6, 12, 24, and 48 h), we found that CAA
affected both parameters in a time-dependent manner.
Decreased cell survival and impairment of phosphate
transport was correlated to incubation time in an exponential
manner (data not shown). Moreover, this effect was also dose
dependent. Thus, Figure 1 shows the effect of 24 h incubation
with different concentrations of CAA on cell survival and Na-
dependent Pi uptake in OK cells. CAA led to cell death only
at concentrations above 250 mM (Figure 1a). However, Pi
transport was significantly impaired, in a dose-dependent
manner, after incubation with a non-lethal concentration of
CAA (Figure 1b). This effect was already evident at 50 mM
CAA, and incubation with 100 mM CAA inhibited Pi transport
to the same extent as incubation with 108 M PTH for 4 h.
Both cell death and impairment of Pi transport were
completely inhibitable by coincubation with 1 mM MESNA
(Figure 1d and e). Noteworthy coincubation with MESNA or
DiMESNA did not lead to enhanced susceptibility of cells. As
shown by Western blot (Figure 1c), incubation with CAA led
to a dose-dependent decrease in NaPi-IIa protein that
paralleled the changes on Na-dependent Pi uptake (compare
Figure 1b and c). No changes in concentrations of NHE3 or
Na-K-ATPase could be found.
Figure 2 shows immunofluorescence of the endogenous
NaPi-IIa and b-actin after incubation of OK cells with the
different metabolites. Corresponding to Western blotting, CAA
incubation led to a reduction in apical NaPi-IIa expression.
4-OH-Ifo
Similar to CAA, 4-OH-Ifo decreased cell survival and Na-
dependent Pi uptake in a time-dependent manner (data not
shown). Experiments investigating the concentration depen-
dency of cell survival showed similar data compared with
CAA, but 4-OH-Ifo was slightly more toxic (Figure 3a). Na-
dependent Pi uptake was significantly reduced after 24 h
incubation in the presence of 4-OH-Ifo concentrations that
did not affect cell survival (Figure 3b). MESNA was able to
prevent the cell death induced by up to 500 mM 4-OH-Ifo
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(Figure 3d); however, it could not inhibit the effect of 4-OH-
Ifo on Pi transport. Western blotting showed that incubation
with 4-OH-Ifo resulted in a dose-dependent reduction in
NaPi-IIa protein; as for CAA, the reduction in NaPi-IIa
mirrored the changes in Na-dependent Pi uptake (compare
Figure 3b and c). No changes in NHE3 or Na-K-ATPase levels
were detected. The changes in NaPi-IIa abundance were
compatible with the immunofluorescence data (Figure 2).
Ifo-mustard
OK cells were relatively resistant to incubation with
Ifosfamide-mustard (Ifo-mustard). Incubation with 500 mM
for 24 h was required to detect significant impairment of cell
survival, but 50 mM were already able to inhibit Pi transport
significantly (Figure 4a and b). Incubation with 50 and
100 mM/6 h did not alter Pi transport (data not shown). In
contrast to CAA and 4-OH-Ifo coincubation with MESNA
was without any effect regarding cell survival (Figure 4d) and
Pi transport (Figure 4e). Again reduction of Pi transport was
caused by reduction in NaPi-IIa levels as detected by Western
blot (Figure 4c) and immunofluorescence (Figure 2). Unlike
PTH, Ifo-mustard also inhibited the sodium-dependent
glutamic acid cotransporter, another sodium-dependent
apical cotransporter, although this effect was only observed
at 100 mM (Figure 4f).
In order to clarify whether Ifo-mustard acts on NaPi-IIa-
like PTH, that is, via internalization and lysosomal degrada-
tion of the transporter, coincubation experiments with
leupeptin were carried out (Figure 5). It is known that
leupeptin inhibits lysosomal degradation of NaPi-IIa upon
PTH treatment32 (Figure 5b). After coincubation of Ifo-
mustard and leupeptin more NaPi-IIa protein could be found
compared with incubation with Ifo-mustard alone (Figure
5b). The Western blotting data could be confirmed by
CAA (M)/24 h
CAA (M)/24 h
CAA (M)/24 h
0
0 1 5 10 20 50 100 250 500
50
100
150 n = 12
n = 9 n = 6
n = 12
*
*R
el
at
iv
e 
ce
ll 
su
rv
iv
al
 (%
)
0 10 100 250 500
0
50
100
150
CAA + MESNA 1 mM
*
116 kDa
97 kDa
NaPi-IIa
 97 kDa
NHE3
42 kDa -Actin
0 10 50 100 PTH
0
50
100
97 kDa Na-K-ATPase
*
*
*
150
N
a/
Pi
-c
ot
ra
ns
po
rt 
ac
tiv
ity
 (%
)
0
50
100
150
co MESNA
1 mM/24 h
CAA
100 M/24 h
CAA +
MESNA
*
+
a d
b
c
e
Figure 1 | Modification of cell survival, Na/Pi cotransport, and protein expression by metabolite incubation schemes. Effect of 24-h
incubation with CAA on (a) cell survival, (b) Na/Pi cotransport, and on (c) protein expression of NaPi-IIa, Na-K-ATPase, NHE3, and b-actin in OK
cells. Each lane in (c) resembles the corresponding concentration at (b); incubation with PTH (108 M/4 h) served as positive controls. (d) Effect
of coincubation with CAA and 1 mM MESNA on cell survival and (e) on Na/Pi cotransport.
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immunofluorescence (Figure 5c). These findings suggest that
Ifo-mustard acts, at least partially, via increased endocytosis
and lysosomal degradation of the NaPi-IIa transporter. The
level of expression of NHE3, Na-K-ATPase, and b-actin was
not altered by these incubation conditions (Figure 5b).
CyP-mustard
Twenty-four-hour incubation with cyclophosphamide-
mustard (CyP-mustard) did not have any influence on cell
survival of OK cells up to 1000 mM. The inhibitory effect on Pi
transport and on NaPi-IIa protein was the same as found
after Ifo-mustard incubation (data not shown).
Northern blotting
Figure 6 show the result of Northern blotting after incubation
with 50 mM CAA, 4-OH-Ifo, Ifo-mustard, and CyP-mustard
for 24 h and with 108 M PTH for 4 h. After densitometry,
NaPi-IIa mRNA was expressed as a percentage of b-actin. As
expected, PTH did not decrease NaPi-IIa mRNA levels.
However, Ifo-mustard and 4-OH-Ifo led to a pronounced
decrease and CAA to slight reduction in Napi-IIa mRNA.
Long-term effects of mustards
For these experiments, a different incubation protocol was
used. Cells were already incubated with Ifo-mustard or CyP-
mustard 7 h after seeding for 24 h. Then, incubations were
conducted with normal a medium for an additional 72 h. In
all, concentrations tested (10 and 50 mM) confluent mono-
layers developed with large, dysplastic cells with abnormal
amounts of nuclei. As shown in Figure 7, Pi transport was
impaired significantly in these cells.
DISCUSSION
The mechanism of tubulopathy after Ifo treatment in
children is not fully understood yet.3 One important point
seems to be the difference in metabolism between Ifo and the
isomeric CyP, because neither FS nor proximal tubular
damage have been reported following a treatment with the
latter drug. Investigations describing CAA as a main
metabolite causing renal FS describe changes in cell
metabolism that are compatible with acute toxicity in the
sense of dying cells. However, it appears difficult to explain
some hallmarks of Ifo-induced FS by this model such as the
first appearance not until months after the end of therapy.
Furthermore, in nearly all publications the action of CAA was
prevented by MESNA.
As the clinical situation of renal FS after Ifo is not a
scenario of dying tubular cells and not preventable by
MESNA, we assumed it would rather be a dysfunction of
surviving renal tubular cells, probably specific dysfunction
of apical transport systems rather than a general impairment
of tubule cells by necrosis and apoptosis. Therefore, we
defined OK-cell survival by 3-[4,5]dimethylthiazol-2,5-
diphenyltetrazolium bromide test and looked for Pi-transport
dysfunction in non-lethal conditions. OK cells represent a
renal proximal tubular model, at least regarding the handling
of Pi. They express an endogenous type IIa sodium phosphate
cotransporter (NaPi-IIa) located in the apical membrane and
regulated by many of the hormonal and non-hormonal
factors that regulate proximal reabsorption of Pi.
As expected, neither Ifo nor CyP had any effect on cell
survival or Pi transport in incubation with up to 1000 mM/
24 h. These concentrations are above the physiological serum
NaPi-IIa
-Actin
Merge
Control PTH CAA 4 -OH-Ifo Ifo-mustard CyP-mustard
Figure 2 | Effect of incubation with PTH (108 M/4 h), CAA (50 lM/24 h), 4-OH-Ifo (50 lM/24 h), Ifo-mustard (50 lM/24 h), and CyP-mustard
(50 lM/24 h) on immunofluorecence of NaPi-IIa (green) and b-actin (red) in OK cells via confocal microscopy. Yellow color indicates
colocalization of NaPi-IIa with b-actin; each set of pictures contains an apically located focal plane and corresponding cross sections.
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concentrations of about 50–800 mM (Ifo) and 400 mM (CyP)
and in accordance with the literature.8,31,33–41 Nevertheless,
we could not clarify whether some metabolism of Ifo or
CyP to toxic metabolites, especially CAA, takes place in OK
cells.
Until now, CAA has been considered as the most likely
metabolite to cause renal FS. We could demonstrate dose-
and time-dependent toxic effects of CAA on cell survival, on
Pi transport, and on NaPi-IIa expression. Using NHS-biotiny-
lation and terminal deoxy transferase uridine triphosphate
nick end labeling-assay, we showed that incubation with high
dosages of CAA causes necrosis (data not shown). This is in
correlation with published ATP depletion,12,13,42,43 lactate
dehydrogenase release, and CoA and glutathione depletions43
after CAA incubation. All these effects could be prevented
by MESNA, whereas DiMESNA did not have any effect.
This makes absorption of DiMESNA and intracellular
oxidation to MESNA in the OK-cell system unlikely. In
summary, CAA at low concentrations was able to impair Pi
transport by reducing NaPi-IIa expression in viable cells.
High concentrations caused necrotic cell death. However,
because MESNA was able to neutralize all these effects
completely, the role of CAA in vivo as important for FS seems
uncertain.
4-OH-Ifo was found to have similar but slightly more
toxic effects than CAA on OK cells. Surprisingly, its effect on
Pi transport could not be prevented by MESNA.
Effects of oxazaphosphorine mustards on apical transport
systems in renal tubular cells have not been published yet.
According to the literature,44 OK cells were resistant to
incubation with a high concentration of Ifo-mustard
(500 mM/24) or CyP-mustard (1000 mM/24 h) regarding cell
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Figure 3 | Modification of cell survival, Na/Pi cotransport, and protein expression by metabolite incubation schemes. Effect of 24-h
incubation with 4-OH-Ifo on (a) cell survival, (b) Na/Pi cotransport, and on (c) protein expression of NaPi-IIa, Na-K-ATPase, NHE3, and b-actin
in OK cells. Each lane in (c) resembles the corresponding concentration at (b); incubation with PTH (108 M/4 h) served as positive controls.
(d) Effect of coincubation with 4-OH-Ifo and 1 mM MESNA on cell survival and (e) on Na/Pi cotransport.
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survival. Serum concentrations of mustards during Ifo
treatment in vivo were found between 5 and 120 mM,37,40,45
but concentrations within the renal tubule are not known.46
Furthermore, some authors consider intracellular concentra-
tion47 or serum concentration expressed as an area under the
curve as more relevant for cytotoxic action. MESNA was
without any effect when incubated together with Ifo-
mustard. It means that MESNA did not prevent toxicity
nor did it increase toxicity in our system. After incubation for
24 h at concentrations as low as of 50 mM Ifo-mustard, we
already found significant impairment of Pi transport caused
by reduction of NaPi-IIa expression in viable cells. We were
able to show that this reduction is owing to internalization
and lysosomal degradation of NaPi-IIa, a mechanism
similar to that of PTH. This indicates that the intracellular
scaffolding and energy supply necessary for retrieval of
apical transporters are sufficient. Furthermore, the
reduction of NaPi-IIa after Ifo-mustard incubation is
probably also caused by impaired de novo synthesis, as
the mRNA levels were reduced also. It is known that the
cytotoxic action of oxazaphosphorines takes place via
intercalation with double strands of DNA causing inhibition
of transcription.48–51
The findings after CyP-mustard treatment are surprising.
Given the analogous inhibitory effect on Pi transport, one
would expect at least some reports about phosphate loss after
CyP treatment. These reports are rare.52 Nevertheless,
interindividual differences in pharmacogenetics and different
susceptibility of renal proximal tubular cells in vivo need to
be considered to speculate on this finding.
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Figure 4 | Modification of cell survival, Na/Pi cotransport, and protein expression by metabolite incubation schemes. Effect
of 24-h incubation with Ifo-mustard on (a) cell survival, (b) Na/Pi cotransport, and on (c) protein expression of NaPi-IIa, Na-K-ATPase, NHE3, and
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(f) Effect on Na/glutamic acid cotransport.
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In all cases, we found that only NaPi-IIa but no NHE3 and
Na-K-ATPase expression was influenced by toxic metabolites.
This may be explained by two characteristic features of NaPi-
IIa. It is because of its stoichiometric characteristics highly
dependent on transmembranous sodium gradient and
because it is not recycled after internalization (in contrast
to NHE3) impairment of de novo synthesis is difficult to
compensate.
We did not investigate the cellular energy status as ATP
concentration or the glutathione system status of OK cells
after incubation with different metabolites. Therefore, we are
not able to draw conclusions as to whether inhibition of Pi
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transport and NaPi-IIa expression may be caused by primary
changes within these two systems.
It is difficult to explain why tubulopathy usually becomes
apparent months or even years after the end of Ifo treatment.
This cannot be explained by the ‘acute effect’ experiments,
but the long-term results may offer some hypothesis. Thus, it
may be possible that the mustard-induced defects of the
apical transport system are DNA-bound and therefore may
be passed on to the next generation of cells.
Conclusion
CAA, 4-OH-Ifo, CyP-mustard, and Ifo-mustard are able to
inhibit sodium-dependent phosphate cotransport in viable
OK cells, and the Ifo-mustard effect at least takes place via
internalization and reduction of de novo synthesis of NaPi-
IIa. Ifo-mustard may possibly play an important role in
pathogenesis of Ifo-induced nephropathy. We show evidence
that the tubulopathy after Ifo-treatment may be caused by
specific effects and not just by the toxic action of CAA as
favored by the literature. Probably, the renal side effects of Ifo
are a combination of acute necrotic cell death induced by
CAA and 4-OH-Ifo that can be partly blocked by MESNA.
The development of replacing new tubular cells may take part
under the influence of Ifo-mustard. This may lead to a
growing number of cells with defects in production,
trafficking, internalization, or degradation of apical transport
proteins and manifestation of tubulopathy some time after
the end of Ifo therapy. The discrepancy between lack of
tubulopathy after CyP administration in a clinical setting and
the similar action of CyP-mustard and Ifo-mustard in our cell
culture model cannot be explained easily. Differences in
metabolism in vivo may play a role. However, clearly our
experiments do not explain the different renal side effects of
Ifo and CyP in clinical circumstances.
MATERIALS AND METHODS
Cell culture
OK cells (clone 3B2, passages 10–35) were maintained and grown in
12- or 96-well plates as published earlier.53 Cells were seeded at a
density of 3879.6 104 cells/ml and were re-fed with fresh medium
every 24 h until reaching confluency. After dome formation, cells
were incubated with Ifo, CAA, 4-OH-Ifo, Ifo-mustard, CyP, and
CyP-mustard (courtesy of ASTA Medica, Frankfurt, Germany), in
the absence or presence of MESNA or DiMESNA. Incubations were
carried out for different lengths of time and with different
concentrations. In case of incubation longer than 24 h, medium
and metabolite was changed every 24 h.
Cell survival
Cell survival was assessed by 3-[4,5]dimethylthiazol-2,5-diphenylte-
trazolium bromide test as described elsewhere.44,54 This assay detects
the number of living cells (activity of mitochondrial enzyme
succinate dehydrogenase) measuring the metabolism of the yellow
3-[4,5]dimethylthiazol-2,5-diphenyltetrazolium bromide test into
blue-colored formazan. Cell survival was expressed as a percentage
of controls.
Sodium-dependent PO4 uptake
These studies were performed as described by Reshkin, et al.55 by
measuring 32P uptake in cells grown to confluency on 12-well plates
(Nunc, Wiesbaden, Germany). Transport rates are expressed as pmol
of Pi taken up per mg of total cellular protein, which was determined
by the Lowry protein assay.
For transport assays of glutamic acid, 3H-glutamic acid was
added to the uptake solution.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and Western blotting
These studies were carried out as previously reported by our lab.53
The following antibodies were used: anti-b-actin (mouse) 1:6000
(Sigma-Aldrich, St Louis, MO, USA), anti-Naþ /Kþ -ATPase (alpha
subunit; monoclonal anti-mouse) 1:10 000 (Upstate Biotech, Lake
Placid, NY, USA), or anti-NHE3 (polyclonal anti-rabbit) 1:300
(courtesy Dr OW Moe, Dallas, TX, USA). The endogenous NaPi-IIa
protein was detected using a polyclonal antiserum raised against the
C-terminal 12 amino acids56 (dilution 1:2000 in Blotto-TX-100;
courtesy of E Lederer, PhD, Division of Nephrology, University of
Louisville, Louisville).
mRNA preparation and Northern blotting
OK cells were grown to confluency in 58 cm2 Petri dishes and
incubated with test substances. RNA preparation and Northern
blotting was performed with standard techniques as described
earlier by Sorribas et al.57 Exposition took place at 801C on Kodak
BioMax film. These films were scanned and analyzed by densito-
metry with ImageQuant (Molecular Dynamics, Sunnyvale, CA,
USA).
Immunofluorescence
OK cells were grown to confluency on coverslips as described by
Reshkin et al.55 and incubated with test substances. After washing,
fixation, and permeabilization, cells were incubated with anti-NaPi-
IIa antiserum diluted at 1:100 in phosphate-buffered saline/saponin
for 2 h at room temperature. Thereafter, cells were incubated with
fluorescein isothiocyanate-labeled, anti-rabbit-conjugated IgG (Da-
kopatts, Denmark) and Texas red X-phalloidin (Molecular Probes,
Eugene, OR, USA) in phosphate-buffered saline/saponin. After incu-
bation and washing, coverslips were mounted using Dako-Glycergel
(Dako Corp., Carpinteria, CA, USA) plus 2.5% l,4-diazabicyclo-
[2.2.2]octane (Sigma-Aldrich) as a fading retardant. Immunofluor-
escence was revealed by confocal microscopy (Leica laser scan
microscope TCSSP, Wetzlar, Germany) at original magnification
 40.
Presentation of the results. All experiments were performed
independently at least twice. Statistical results are expressed as
mean7s.d. Results of the 3-[4,5]dimethylthiazol-2,5-diphenyltetra-
zolium bromide test, 32PO4- and
3H-glutamic acid uptake are
expressed as a percentage of controls. Test of significance was
performed by univariate analysis of variance with repeated measures
and Greenhouse–Geisser correction. Significance was accepted at
Po0.05. Western blot and immunofluorescence experiments were
repeated at least twice, and one representative experiment was
chosen for presentation.
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